Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin's lymphoma

J Oncol Pharm Pract. 2017 Jan;23(1):71-74. doi: 10.1177/1078155215620922. Epub 2016 Jul 9.

Abstract

Posterior reversible encephalopathy syndrome (PRES) is characterized by a group of central nervous system related symptoms. Diagnosis is usually made by computed tomography or magnetic resonance imaging. Common causes can be arterial hypertension, sepsis, autoimmune disorders, and medications. We report PRES in a relapsed Hodgkin's Lymphoma patient after a dose of pembrolizumab.

Keywords: Hodgkin; Keytruda; PRES; encephalopathy syndrome; pembrolizumab; posterior reversible.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Hodgkin Disease / drug therapy*
  • Humans
  • Posterior Leukoencephalopathy Syndrome / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • pembrolizumab